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Hip fracture is a common trauma in older adults with a high incidence of depression, which relates to
poorer prognosis including increased risk of infection. Ageing is accompanied by reduced immunity,
termed immunesenescence, resulting in increased susceptibility to infection. We examined whether
physical trauma (hip fracture) and psychological distress (depressive symptoms) had additive effects
upon the aged immune system that might contribute to poor outcomes after injury. Neutrophil function
was assessed in 101 hip fracture patients (81 female) 6 weeks and 6 months after injury and 43 healthy
age-matched controls (28 female). Thirty eight fracture patients had depressive symptoms at 6 weeks. No
difference in neutrophil phagocytosis of Escherichia coli was observed between controls and hip fracture
patients, but superoxide production was signiﬁcantly reduced in hip fracture patients with depressive
symptoms compared with patients without symptoms (p = .001) or controls (p = .004) at 6 weeks. Super-
oxide production improved 6 months following fracture to the level seen in controls. We detected ele-
vated serum cortisol, reduced dehydroepiandrosterone sulphate (DHEAS) and an increased
cortisol:DHEAS ratio in fracture patients with depressive symptoms compared with patients without
depressive symptoms or controls at 6 weeks and 6 months after injury. Serum IL6, TNFa and IL10 were
higher among patients with depressive symptoms at 6 weeks. The cortisol:DHEAS ratio and IL6 levels
related to depressive symptom scores but not to neutrophil function. In conclusion, depressive symptoms
related to poorer neutrophil function after hip fracture, but this was not driven by changes in stress hor-
mone or cytokine levels.
 2013 The Authors. Published by Elsevier Inc. Open access under CC BY license.1. Introduction
Hip fracture is a devastating condition and a major health issue
in old age (Abrahamsen et al., 2009). In the UK alone 370,000 older
adults fall each year and 76,000 of these falls result in hip fracture
(Johnell et al., 1992). Even though hip fracture is treatable, it is a
severe physical stressor for older individuals accompanied by in-
creased mortality (Roberts and Goldacre, 2003), immobilisation
and physical disability (Magaziner et al., 2000) resulting in loss
of independence and impaired quality of life. The factors contribut-
ing to poor outcome after hip fracture remain poorly understood.
Healthy older individuals have been reported to experience
greater levels of stress, anxiousness and depression than youngadults (Luz et al., 2003). Stressful life events such as bereavement,
or a disabling medical event are amongst the most potent factors
that can trigger depressive symptoms (Cole and Dendukuri,
2003) and are both more likely to occur in old age. It is perhaps
not surprising that a high rate of depression (9–47%) has been re-
ported in UK and US based studies of older adults with hip fracture
(Holmes and House, 2000). Importantly, depression in hip fracture
patients has been associated with increased risk of infections and
poor survival (Nightingale et al., 2001), impaired recovery and a re-
tarded ability to regain pre-fracture levels of physical functioning
(Mossey et al., 1990).
It is well documented that ageing is accompanied by immune
dysregulation (Dorshkind et al., 2009; Panda et al., 2009), termed
immunesenescence, which contributes to the increased risk of
infection in old age (Gavazzi and Krause, 2002). Interestingly, there
is accumulating evidence suggesting that the effects of stress and
age are interactive, with chronic stress exacerbating the effects of
ageing in older adults (Kiecolt-Glaser and Glaser, 1999). For exam-
ple, a study examining the effect of the chronic stress of care giving
on vaccine responses reported that even though there was a deﬁcit
in the vaccine response of young caregivers when compared with
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caregivers (Kiecolt-Glaser et al., 1996). Additionally, our previous
study reporting a negative association between exposure to stress-
ful life events such as bereavement and marital dissatisfaction and
antibody responses to vaccination, reported a signiﬁcant positive
effect of marital satisfaction on the response to vaccination in older
adults (Phillips et al., 2006). Our own work has also shown that in-
nate immunity is susceptible to the effects of stress, with neutrophil
superoxide generation reduced in old hip fracture patients (Butcher
et al., 2003) and bereaved older adults (Khanfer et al., 2011).
The hypothalamus–pituitary–adrenal (HPA) axis acts as a piv-
otal regulator of the stress responses by mobilising energy reserves
and modulating immune responses (Tsigos and Chrousos, 2002).
Glucocorticoids (GCs), namely cortisol in humans, are key effectors
of the HPA axis and are potent immune suppressors. Dehydroepi-
androsterone sulphate (DHEAS), a major steroid produced by the
adrenal gland, has been reported to have anti-depressive, anti-glu-
cocorticoid and immune-enhancing properties, including increased
neutrophil superoxide generation (Hazeldine et al., 2010; Radford
et al., 2010). Some previous studies have suggested that healthy
ageing is accompanied by hyperactivation of the HPA axis, espe-
cially in situations of chronic stress resulting in prolonged expo-
sure to cortisol (Aguilera, 2011). However, studies examining the
effects of ageing on diurnal cortisol secretion have yielded conﬂict-
ing results, with either a ﬂattening of the diurnal pattern of secre-
tion with increasing age (Deuschle et al., 1997; Luz et al., 2003; Van
Cauter et al., 1996; Yen and Laughlin, 1998), no association (Ed-
wards et al., 2001; Wolf et al., 2002), or decreased overall levels
(Orentreich et al., 1992; Straub et al., 2000) with age. In contrast,
the serum level of DHEAS reaches peak concentrations during the
third decade of life, after which a steady decline occurs with age
(1–2% per year); such that by the age of 80, DHEAS levels have
reached 10–20% of their peak level (Vermeulen, 1995). Therefore,
the current literature suggests that although serum cortisol may
not increase markedly with ageing, cortisol levels are higher in
relation to other hormones such as DHEAS and ageing is accompa-
nied by an elevated cortisol:DHEAS ratio which may be a key factor
contributing towards age associated immune dysregulation (Bu-
ford and Willoughby, 2008) and which might be heightened by
chronic stress. In a previous study, our group reported a raised cor-
tisol:DHEAS ratio in old hip fracture patients compared to compa-
rable young trauma patients and this enhanced glucocorticoid
response was also accompanied by reduced neutrophil superoxide
generation and increased incidence of infection (Butcher et al.,
2005). This study did not consider other factors that might inﬂu-
ence immunity after hip fracture. Further, both ageing ((Franceschi
et al., 2007; Krabbe et al., 2004)), and depression (Dowlati et al.,
2010; Leonard, 2010; Zunszain et al., 2012) are accompanied by
a switch towards a pro-inﬂammatory state, which can be seen in
the levels of different pro- and anti-inﬂammatory cytokines. These
cytokines have profound effects on immune cells and might also
inﬂuence neutrophil function (Hellberg et al., 2011).
The present study sought to test the hypothesis that psycholog-
ical distress, speciﬁcally depressive symptoms, would act addi-
tively with the physical stress of hip fracture to amplify the
effect of ageing upon immunity (immunesenescence), with speciﬁc
reference to neutrophil function. It also examined the role of the
cortisol:DHEAS ratio and pro- and anti-inﬂammatory cytokines as
potential mediators of any additive effects observed.
2. Methods
2.1. Participants
One hundred and one older hip fracture patients (two partici-
pants were excluded after consenting as it became apparent thatthey did not in fact meet the inclusion criteria) were recruited from
ﬁve hospitals in Birmingham, UK between 2010 and 2012. Thirty-
seven (26%) were male. Inclusion criteria were that participants
had to be aged 60 years and over with a hip fracture sustained
4–6 weeks previously but with no chronic immune-related disor-
ders e.g., cancer, diabetes, or taking any regular medications that
might modify immunity, e.g., immunosuppressants, statins. Addi-
tionally patients must not have had any diagnosis of depression
by a physician prior to age 50 years or be taking or have previously
taken anti-depressant medication, in order to pick up patients with
depressive symptoms emerging post-hip fracture rather than those
with a prior history of and thus propensity to depression. Partici-
pants started on anti-depressant treatment, therapy, or any change
that would mean they no longer met the inclusion criteria between
week 6 and month 6 testing sessions were excluded. Forty-three
healthy older adults, 17 male, (40%), were also recruited from the
community as controls via invitation letters to the Birmingham
1000 Elders cohort of healthy older adults involved in current re-
search at the University of Birmingham. These controls also had
to meet the inclusion criteria above but not have a current hip frac-
ture. The study was approved by South Birmingham Local Research
Ethics Committee and all participants provided written informed
consent (study ref: 09/H1203/80).2.2. Study design and procedure
The study was a prospective case-control design with three
groups of older adults: hip fracture patients with or without
depressive symptoms and healthy older adults. Consent was
gained whilst patients were still in hospital. All patients provided
a blood sample and completed questionnaires and structured
interviews 4–6 weeks and 6 months after hip fracture. Control par-
ticipants attended the University, at the same time as we were
sampling a hip fracture patient, for one-off blood sampling and
completed a depression and anxiety symptoms scale and basic
demographic information (see below) following the blood sample.
Blood samples were taken between 09.00 and 11.00 to minimise
any effect of diurnal variations in steroid levels. None of the partic-
ipants had an acute infection at the time of blood sampling. Inter-
views were performed either in the hospital or in the patient’s
home for hip fracture patients and at the university for control par-
ticipants. Assays for neutrophil phagocytosis and superoxide pro-
duction were performed on the same day as blood sampling.
Serum was frozen for later hormone and cytokine analysis. Cyto-
kines were only assessed at the six week time point.2.3. Interview and questionnaires
Standard socio-demographic and health behaviour information
were taken and all comorbidities and medications, prescription
and over-the-counter, were recorded by the interviewer. The psy-
chological status of the participant was assessed by means of
standardised psychometric questionnaires. Depression was evalu-
ated by a Geriatric Depression Scale (GDS) (Yesavage et al.,
1982). Depression was deﬁned as a GDS score greater than or equal
to 6 (Sheikh and Yesavage, 1986). The Hospital Anxiety and
Depression Scale (HADS) was also used to measure depression
and anxiety (Zigmond and Snaith, 1983). The scale contains 14
items, scored from 0 (not present) to 3 (considerable), with seven
assessing aspects of depression and seven assessing anxiety.
Healthy control participants completed the HADS depression
sub-scale in order to check that they did not have signiﬁcant
depressive symptoms. A cut-off of P8 has previously been used
to indicate possible depression (Bjelland et al., 2002).
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Neutrophil phagocytosis was measured in whole blood using a
commercially available kit (Phagotest kit, Orpegen Pharma, Ger-
many) and the assays were performed according to manufacturer’s
instructions. Brieﬂy, FITC-labelled opsonised Escherichia coli were
added to whole blood and incubated at 37 C for 10 min and the
control tube was kept on ice for 10 min. Following incubation,
quenching solution was added to each tube to stop the reaction
and red blood cells were lysed. Following the lysis step the cell sus-
pension was resuspended in DNA staining solution and ﬂuores-
cence analysed immediately using a CyanTM ADP ﬂow cytometer
(Dako Ltd., Cambridge, UK). Data were analysed using Summit cV
4.3. The phagocytic index was used as a measurement of the phag-
ocytic capabilities of neutrophils and was calculated as the per-
centage of cells that had ingested bacteria, multiplied by the
mean ﬂuorescence intensity (MFI), divided by 100. The coefﬁcient
of variation (CV) for the intra-assay variation was 5.1%.
Neutrophil superoxide burst was measured in whole blood
using a commercially available kit (Phagoburst kit, Orpegen Phar-
ma). The assays were performed according to manufacturer’s
instructions. Brieﬂy, whole blood was treated with 100 nM fMLP
(Sigma Aldrich, Poole, UK), 20 nM PMA (Sigma Aldrich) or opson-
ised E. coli at 37 C for 10 min. Following incubation, ﬂuorogenic
substrate dihydrorhodamine (DHR) 123 was added to the blood
sample at 37 C for ten minutes. Post incubation, cells were lysed
after which DNA staining solution was added. Oxidation of sub-
strate DHR123 was analysed by ﬂow Cytometry using a CyanTM
ADP ﬂow cytometer. The oxidative burst production is indicated
by the MFI of the neutrophil population. The coefﬁcient of variation
(CV) for the intra-assay variation was 3.2%.
2.5. Serum cortisol and DHEAS assays
Serum cortisol and DHEAS levels were measured by ELISA using
a commercial kit (IBL international, Hamburg, Germany) according
to manufacturer’s instructions. Intra assay coefﬁcients of variation
(CV%) were 6.7 for cortisol and 4.6 for DHEAS ELISAs.
2.6. Cytokine assays
A multiplex based assay for the cytokines IL1b, IL4, IL6, IL10,
and TNFa (Bio-Rad Laboratories, Munich, Germany) was per-
formed according to manufacturer’s instructions. Data acquisition
and analysis was conducted using Bio-Plex Manager software ver-
sion 6.0. Intra assay coefﬁcients of variation (CV%) ranged from
7.15 to 13.89.
2.7. Statistical analysis
Univariate ANOVA with least signiﬁcant difference post hoc
tests were used to assess differences between the three groups
(hip fracture with depressive symptoms, hip fracture without
depressive symptoms, and healthy controls). Where demographic
variables differed signiﬁcantly between the three groups, analyses
were rerun adjusting for these variables using ANCOVA. Pearson’s
correlations were used to examine associations between depres-
sion score and neutrophil function and hormone levels. Where
there were group differences in demographic or health behaviour
variables, linear regression analyses were run with signiﬁcant
covariates entered at step 1. In order to test for potential mediation
between depression and any effects on immune function by the
cortisol:DHEAS ratio or cytokines, linear regressions were run pre-
dicting neutrophil function from hip fracture group entered at step
1 in the model, and the cortisol:DHEAS ratio or cytokine variable
entered at step 2. Differences in degrees of freedom reﬂect occa-sional missing data. Data was missing where there was not sufﬁ-
cient serum for analyses, or the expense of multiple assays
prohibited further analysis once the sample size needed by power
analyses was complete (e.g., neutrophil phagocytosis, granulocyte
numbers). In other cases, (e.g., cytokines) numbers also reﬂect lack
of assay sensitivity for circulating non-stimulated cytokine levels
in a relatively healthy sample. Patients in these reduced size ana-
lytic groups were a random sample of those tested, with the excep-
tion of neutrophil phagocytosis which was conducted on the ﬁrst
116 participants as these are same day assays and sample sizes
from power analyses are generally smaller for this assay.3. Results
3.1. Recruitment and withdrawal
Recruitment and withdrawal data are shown in Fig. 1. Reasons
for withdrawal between week 6 and month 6 included: death or
being too unwell to be tested (N = 17), not being able to continue
in the study for a variety of reasons including feeling they had
too much to cope with, now receiving treatment for depressive
symptoms or other medication/illnesses on the list of exclusion cri-
teria, or being non-contactable (N = 18). There was little evidence
of selection bias between the sample who withdrew or remained
in the study at six months in terms of gender (p = .26), initial
depression group status (p = .72), BMI (p = .34), or number of med-
ications being taken (p = .09). However, those who withdrew were
marginally more likely to be from the manual occupational group,
(p = .05), were, on average, 3.9 years older (p = .02), and had 0.5
more comorbidities on average (p = .03).
3.2. Participant demographics
The demographic statistics and depression and anxiety scores
for the study participants are shown in Table 1. Patients were clas-
siﬁed into two groups on the basis of their GDS scores: hip fracture
patients with a GDS score of 5 or less were classiﬁed as non-de-
pressed (HF; hip fracture only), those with a score of 6 or greater
were categorised as having signiﬁcant depressive symptoms
(HF + D; Hip fracture patients with depressive symptoms). In this
study we observed that 38 (37%) of the hip fracture patients had
depressive symptoms 4–6 weeks after their fracture. There were
signiﬁcant group differences between the controls and the hip frac-
ture group for age and BMI, such that the control group were
slightly younger, had a higher BMI, and more males. Consequently,
all analyses were rerun with adjustment for age, BMI, and sex. As
expected, the hip fracture group with depressive symptoms had
signiﬁcantly higher HADS depression scores than the hip fracture
group without symptoms and the control group. However, there
were no signiﬁcant differences between the two hip fracture
groups in terms of socio-economic status, smoking behaviour or
alcohol consumption. At month 6, data were available for 66 hip
fracture patients; 19 (29%) of whom were depressed.
3.3. Neutrophil count and function in hip fracture patients
We compared granulocyte (mainly neutrophils) counts in
peripheral blood of hip fracture patients with and without depres-
sive symptoms with healthy older adults. There was a signiﬁcant
difference in the granulocyte count between the three groups in
unadjusted analyses (see Table 2), such that the controls had sig-
niﬁcantly lower numbers of granulocytes than the hip fracture pa-
tients with (p = .04) and without depressive symptoms (p = .02),
see Fig. 2a, though all were within the normal range. However,
adjustment for covariates reduced the degrees of freedom due to
Consented (n=200)
Parcipated  at 
Week 6 (n=103 )
Non-depressed (n=65 )
Parcipated at  M6 (n=44)
Analysed (n= 42)
*Excluding 2 parcipants who 
did not meet inclusion criteria
Withdrew prior to Month 6 
(n= 21)
Depressed (n=38 )
Parcipated at M6 (n=24)
Analysed (n=24)
Withdrew prior to Month 6 
(n= 14)
Withdrawal prior  to Week 6 
(n=97 )
Fig. 1. Recruitment and attrition in the study.
Table 1
Participant demographics and questionnaire scores.
Variable Mean (SD)/N (%) p
Controls Hip fracture patients (HF) Hip fracture patients with depressive symptoms (HF + D)
N at week 6 43 65 38
Age 74.9 (5.64) 83.8 (7.48) 84.0 (8.62) <.001
BMI 27.6 (5.02) 23.5 (3.81) 22.7 (4.03) <.001
Sex: male 17 (40) 13 (21) 7 (18) .05
Occupational group: manual – 28 (43) 21 (58) .21
Smokers 2 (8) 7 (11) 6 (19) .60
Alcohol consumption: one or more units per week 13 (50) 24 (37) 13 (34) .43
Number of co-morbidities – 2.2 (1.41) 2.0 (1.28) .40
Number of medications – 4.6 (2.68) 5.3 (2.96) .23
GDS – 2.6 (1.53) 8.2 (2.47) <.001
HADS depression 2.4 (1.71) 3.4 (2.31) 9.1 (4.71) <.001
HADS anxiety – 4.0 (3.71) 8.0 (4.46) <.001
N at month 6 – 47 (71) 19 (29) .72
GDS at month 6 – 2.8 (1.90) 8.7 (2.67) <.001
176 N.A. Duggal et al. / Brain, Behavior, and Immunity 33 (2013) 173–182missing data, thus this difference was no longer signiﬁcant in anal-
yses adjusted for age, BMI, and sex, see Table 3 for fully adjusted
analyses data and effects of covariates.
Neutrophil phagocytosis in older adults did not differ between
the three groups, although controls had slightly lower phagocyto-sis than hip fracture patients without depressive symptoms
(p = .05).
Phagocytosis by neutrophils is followed by killing of ingested
pathogens by production of reactive oxygen species (including
superoxide anion) termed respiratory burst. Neutrophil superoxide
Table 2
Participant immune data by group (unadjusted analyses).
Variable Mean (SD) Statistics
Controls HF HF + D
Granulocyte count (109/L) 3.67 (1.29) 4.84 (1.77) 4.86 (1.68) F(2,66) = 4.76, p = .01, g2 = .12
Phagocytosis (MFI) 207.27 (46.07) 251.64 (98.86) 241.66 (123.69) F(2,112) = 2.29, p = .11, g2 = .039
Superoxide production to PMA (MFI) 101.11(62.95) 91.03 (64.60) 50.46 (29.75) F(2,87) = 5.53, p = .005, g2 = .113
Superoxide production to E. coli (MFI) 68.50 (39.16) 68.87 (43.36) 42.84(22.99) F(2,134) = 6.52, p = .002, g2 = .089
Serum cortisol (mg/mL) .130 (.05) .121 (.04) .169 (.05) F(2,127) = 10.32, p < .001, g2 = .140
Serum DHEAS (mg/mL) .814 (.367) .429 (.792) .184 (.157) F(2,127) = 10.47, p < .001, g2 = .14
Cortisol:DHEAS ratio .288 (.469) .994 (1.67) 2.22(2.81) F(2,127) = 9.36, p < .001, g2 = .12
IL6 6.25 (6.40) 7.31 (5.15) 13.79 (9.75) F(2,101) = 10.25, p < .001, g2 = .169
TNFa 4.28 (4.58) 9.96 (6.06) 19.25 (19.52) F(2, 62) = 9.52, p <.001, g2 = .235
IL1b 18.41 (13.77) 12.84 (7.92) 26.29 (29.62) F(2,58) = 2.05, p = .14, g2 = .066
IL10 5.27(5.34) 10.37 (10.15) 22.41 (28.91) F(2,66) = 7.25, p = .001, g2 = .180
IL4 2.37 (2.21) 1.45 (3.60) 3.37 (9.64) F(2,89) = 0.82, p = .44, g2 = .018
IL13 16.48 (2.67) 7.47 (4.02) 15.84 (3.77) F(2,63) = 1.86, p = .16, g2 = .056
r (97) = -.30, p = .002
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Fig. 2. Neutrophil superoxide production on stimulation with E. coli in hip fracture patients with and without depressive symptoms versus healthy controls. (a) Neutrophil
superoxide production (MFI) for hip fracture patients with (n = 35), or without depressive symptoms (n = 60) and healthy controls (n = 32). The solid bar represents the mean
value and ⁄⁄indicates p < .005. (b) Correlation between GDS scores and neutrophil superoxide generation.
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ses, was signiﬁcant between the three groups (see Tables 2 and 3).
This was also the case for the response to opsonised E. coli. How-
ever, the signiﬁcant impairment was most evident among the hip
fracture patients who developed depressive symptoms: for PMA,
p = .01, compared to controls, and p = .01, compared to hip fracture
alone (data not shown), and for E. coli, p = .09 compared to controls
and p = .003 compared to hip fracture alone. Fig. 2 shows the unad-
justed analyses for E. coli.3.4. Serum cortisol and DHEAS levels in hip fracture patients
Analysis of HPA axis hormone levels revealed signiﬁcant group
differences at week six for serum cortisol in unadjusted and ad-
justed analyses (see Tables 2 and 3); similar results were found
for DHEAS levels. This was driven by signiﬁcantly higher cortisol
in the hip fracture patients with depressive symptoms compared
with patients with hip fracture alone, p < .001 and compared with
controls, p = .04 (see Table 2). There was also lower DHEAS in the
hip fracture patients with depressive symptoms compared with
controls, p = .003, and those with hip fracture alone group, p = .05
(see Table 2). A signiﬁcant group difference in the serum corti-
sol:DHEAS ratio was also observed, see Tables 2 and 3, such that
only those hip fracture patients who developed depressive symp-
toms had a higher ratio when compared with non-depressed pa-
tients, p = .01 and they also had a higher ratio than those with
hip fracture alone, p = .01. Fig. 3 shows the unadjusted values.
However, there was no signiﬁcant association between serum cor-tisol:DHEAS ratio and neutrophil superoxide production in the
whole sample, p = .87, or in hip fracture patients alone, p = .71.
3.5. Serum cytokine levels in hip fracture patients
On examining the serum cytokine levels in hip fracture patients,
there were signiﬁcant differences in serum IL6 levels between the
three groups (Tables 2 and 3), such that a signiﬁcant increase in
serum IL6 levels was observed in hip fracture patients with depres-
sive symptoms compared with non-depressed hip fracture patients
(p = .001), and to healthy controls (p =.02) (Fig. 4a). However, IL6
did not correlate with neutrophil superoxide production, p = .24,
thus showing no likely mediation of the association between
depressive symptoms and reduced neutrophil function by IL6.
Next, on evaluating serum TNFa levels between the three
groups (Tables 2 and 3), there was also a signiﬁcant difference,
such that higher serum TNFa levels were evident among the hip
fracture patients with depressive symptoms compared with
healthy controls (p < .001) and non-depressed hip fracture patients
(p = .008) (Fig. 4b). Healthy controls also had lower TNFa than hip
fracture patients without depressive symptoms (p = .04). There
were no signiﬁcant differences in serum IL1b levels between our
three groups, p = .14 (see Table 2). Further, neutrophil function
did not correlate with either TNFa (p = .47) or IL1b (p = .40), sug-
gesting that these were not mediators of the association between
depressive symptoms and reduced neutrophil function.
On examining the serum levels of anti-inﬂammatory cytokines,
there were signiﬁcant differences in serum IL10 levels between our
three groups (see Tables 2 and 3), in adjusted analyses, such that
Table 3
Adjusted analyses for main signiﬁcant outcomes.
Dependent Variable Variables in Model (df) F p g2
Granulocyte count
Age 0.04 .84 .001
BMI 1.18 .28 .021
Sex 0.26 .62 .005
Depression group 2,55 1.62 .21 .056
Phagocytosis Age 3.72 .06 .036
BMI 1.97 .16 .019
Sex 0.12 .73 .001
Depression group 2,100 2.11 .13 .041
Superoxide production to PMA Age 3.04 .09 .041
BMI 0.03 .86 .000
Sex 1.97 .17 .027
Depression group 2,71 4.75 .01 .118
Superoxide production to E. coli Age 1.80 .18 .015
BMI 3.84 .05 .031
Sex 0.12 .73 .001
Depression group 2,120 4.56 .01 .071
Serum cortisol (mg/mL) Age 0.28 .60 .003
BMI 0.73 .39 .007
Sex 2.23 .14 .020
Depression group 2,111 7.72 .001 .122
Serum DHEAS (mg/mL) Age 3.86 .05 .034
BMI 0.46 .50 .004
Sex 4.65 .03 .040
Depression group 2,111 4.80 .01 .080
Cortisol:DHEAS ratio Age 0.11 .75 .001
BMI 1.33 .25 .012
Sex 0.75 .39 .007
Depression group 2,110 5.00 .008 .083
IL6 Age 6.72 .01 .072
BMI 0.05 .82 .001
Sex 3.17 .08 .035
Depression group 2,87 6.71 .002 .134
TNFa Age 4.51 .04 .078
BMI 0.30 .58 .006
Sex 2.99 .09 .053
Depression group 2,53 8.04 .001 .233
IL10 Age 3.34 .07 .059
BMI 1.19 .28 .022
Sex 0.32 .58 .006
Depression group 2,53 4.43 .02 .143
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Fig. 3. Stress hormone levels in hip fracture patients with and without depressive
symptoms versus healthy controls. (a) cortisol: DHEAS ratio in hip fracture patients
with (n = 35), or without depressive symptoms (n = 54) and healthy controls
(n = 32). Data are mean ± SEM and for ⁄p < .05, ⁄⁄p < .01 and ⁄⁄⁄p < .001.
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Fig. 4. Serum cytokine levels in hip fracture patients with and without depressive
symptoms versus healthy controls. (a) Mean serum IL6 levels for hip fracture
patients with (n = 29), or without depressive symptoms (n = 37) and healthy
controls (n = 28). (b) Mean serum TNFa levels for hip fracture patients with (n = 20),
or without depressive symptoms (n = 21) and healthy controls (n = 23). (c) Mean
serum IL10 levels for hip fracture patients with (n = 20), or without depressive
symptoms (n = 21) and healthy controls (n = 23). Data are mean ± SEM and for
⁄p < .05, ⁄⁄p < .01 and ⁄⁄⁄p < .001.
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ture patients with depressive symptoms compared to healthy con-
trols (p = .006), but no difference in IL10 between hip fracture
patients with depressive symptoms and those who were non-de-
pressed (p = .08). Further, IL10 levels did not quite signiﬁcantly cor-
relate with neutrophil superoxide production (p = .06), thus there
was no evidence of mediation of depressive symptom effects onneutrophil function by IL10. Finally, there were no signiﬁcant dif-
ferences in serum IL4 levels, p = .31, or in serum IL13 levels
p = .40, between the three groups (see Table 2).
3.6. Sensitivity analyses
In order to check for associations with depression scores as a
continuous variable rather than groups split at GDS = 6, regression
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Fig. 5. Neutrophil superoxide generation and cortisol:DHEAS ratio in hip fracture
patients 6 weeks and six months after surgery. Mean neutrophil superoxide
generation for hip fracture patients with (n = 26) or without depressive symptoms
(n = 39) at 6 weeks and 6 months post injury. Data are mean ± SEM and ⁄indicates
p < .05.
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ANCOVA results, in regression analysis, depressive symptom score
itself did not predict granulocyte numbers, b = .01, p = .97,
DR2 = .000. Further, as above, GDS score did not predict phagocyto-
sis among hip fracture patients, b = .01, p = .91, DR2 = .000, but did
predict lower neutrophil superoxide production in hip fracture pa-
tients to PMA, b = .26, p = .05, DR2 = .066, and E. coli, b = .30,
p = .002, DR2 = .092, such that those with a greater symptom score
had poorer superoxide production. Elevated serum cortisol:DHEAS
ratio has been previously reported as a marker for depression
(Young et al., 2002), and in the present study GDS scores, were sig-
niﬁcantly associated with the cortisol:DHEAS ratio, b = .25, p = .01,
DR2 = .063, such that participants with greater depressive symp-
toms had a higher cortisol:DHEAS ratio, again driven by higher cor-
tisol, p < .001, and lower DHEAS, p = .04, in those with more
depressive symptoms. Interestingly, as shown in the ANCOVA
model there was a signiﬁcant association between GDS scores
and IL6 levels in hip fracture patients, b = .29, p = .02, DR2 = .087,
such that those with greater depressive symptoms had higher
IL6. However, the regression model within the hip fracture patients
were not signiﬁcant for the association between depressive symp-
toms and TNFa, b = .19, p = .24, DR2 = .034. Again, as shown above,
in hip fracture patients there were no associations with depressive
symptoms and IL1b (p = .38), IL10 (p = .22), IL4 (p = .82) or IL13
(p = .20). Finally, regression analyses with continuous scores on
the HADS depression subscale for the sample as a whole were also
conducted, and the results were unchanged from those presented
in the ANCOVA models above, with the exception that there was
no longer a signiﬁcant IL6 effect (details available on request from
the authors).3.7. Longer term effects of hip fracture and depressive symptoms
The longer term effect of hip fracture and depressive symptoms
on immune function was also evaluated. On examining neutrophil
function in hip fracture patients six weeks and six months after in-
jury, there was a signiﬁcant main effect of time overall for hip frac-
ture patients, F(1,56) = 6.83, p = .01, g2 = .109, such that superoxide
production improved in both groups. There was also a main effect
of group overall, F(1,56) = 4.12, p = .05, g2 = .068, such that the hip
fracture patients with depressive symptoms had lower overall
neutrophil function. However, the signiﬁcant improvement in
superoxide production over time in both groups meant that by
six months, neutrophil function did not differ between the groups,
p = .34, or relate to week 6 GDS score, p = .36, see Fig. 5.
On measuring serum hormone levels in hip fracture patients
with depression six weeks and six months after injury there was
no signiﬁcant effect of time on the serum cortisol:DHEAS ratio,
F(1,51) = 0.94, p = .34, g2 = .018, such that the ratio did not signiﬁ-
cantly alter overall. However, there remained a signiﬁcant effect of
group, F(1,51) = 7.54, p = .008, g2 = .129, such that the ratio was
higher in the group with depressive symptoms overall and specif-
ically at six months (p = .02) even though 11 of the previously
depressed patients were now classiﬁed as non-depressed by six
months. Correlation analyses with week 6 GDS score conﬁrmed
this, r(52) = .40, p = .003.4. Discussion
In the present study, one third of patients had signiﬁcant
depressive symptoms post-hip fracture. These symptoms were
associated with poorer neutrophil superoxide production and a
higher cortisol:DHEAS ratio, as well as greater levels of the cyto-
kines IL6 and TNFa and lower IL10, compared to healthy controls
and hip fracture patients without depressive symptoms. Thisshows the potential impact of depressive symptoms which were
independently related to immune function, rather than acting as
an additive effect on top of hip fracture alone. However, the corti-
sol:DHEAS ratio and cytokine levels were not associated with neu-
trophil function, thus suggesting that depressive symptoms were
independently associated with reduced superoxide production
and that this is mediated through mechanisms other than those
measured here.
The prevalence of depressive symptoms in the present study is
in line with previous reports (Nightingale et al., 2001). Although
mood disorders, especially depression, have been well studied in
older patients with fractured neck of femur (Holmes and House,
2000; Lenze et al., 2007), this study has demonstrated for the ﬁrst
time that elevated depressive symptoms in these patients are asso-
ciated with immune suppression. Crucially, neutrophil superoxide
production was only impaired in those hip fracture patients that
developed depressive symptoms; those with hip fracture alone
showed neutrophil superoxide production equivalent to that of
the healthy age-matched controls. This suppressed neutrophil
superoxide production observed in hip fracture patients with
depressive symptoms did not persist six months after injury and
improved during that period.
We have previously reported that neutrophil superoxide pro-
duction, speciﬁcally superoxide generation, was suppressed in old-
er (>65 years) hip fracture patients, but not in younger trauma
patients (Butcher et al., 2005). Moreover, we also reported that
hip fracture was associated with a raised cortisol:DHEAS ratio that
might mediate the effects of physical stress on neutrophil superox-
ide generation. However, in that study we did not determine the
factors that were inﬂuencing the raised cortisol:DHEAS ratio and
suppressed neutrophil function, thus we did not, for example,
determine whether patients had depressive symptoms or not.
The data described here reveal the important ﬁnding that depres-
sive symptoms post-fracture in the absence of a prior history of
depression appears to be strongly associated with reduced neutro-
phil function after injury. In addition we found that the altered lev-
els of cortisol, DHEAS and their ratio were also only observed in the
patients who developed depression and did not recover by six
months post-fracture. Interestingly, we found an association be-
tween the cortisol:DHEAS ratio and depression score, but no asso-
ciation with reduced neutrophil superoxide generation, suggesting
that factors other than altered HPA axis functioning are mediating
the association between depression and neutrophil superoxide
production.
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logical wellbeing and HPA axis activity and increased cortisol levels
is one of the most consistent ﬁndings in depressed patients (Burke
et al., 2005; Gold et al., 1988), due to altered functioning of the glu-
cocorticoid receptor (Zunszain et al., 2011). A decline in DHEAS
levels in depressed patients has been reported to negatively corre-
late with a rating of depressed mood (Maninger et al., 2009). In the
present study we observed an elevated serum cortisol:DHEAS ratio
in hip fracture patients with depressive symptoms, due to in-
creased serum cortisol levels and lower DHEAS levels, which is
consistent with these previous studies.
It is well documented that ageing is accompanied by alterations
in neutrophil bactericidal properties, including their ability to de-
stroy ingested pathogens by superoxide generation (Panda et al.,
2009; Wenisch et al., 2000). Emotional states such as depression
are also known suppressors of immune function, for instance a
study examining the effect of depression among children on neu-
trophil functioning has reported suppressed neutrophil superoxide
generation with depression (Bartlett et al., 1997). In this study we
have examined for the ﬁrst time the additive effect of physical
stress or trauma and psychological distress on immune dysregula-
tion in older adults. Our ﬁndings are consistent with studies that
have associated emotional stressors, such as bereavement in older
adults with impaired neutrophil superoxide generation and failed
to report an effect of such psychological distress on neutrophil
phagocytic ability (Khanfer et al., 2011). Neutrophils play a prime
role in defence against bacterial infections, thus this reduction in
neutrophil superoxide production observed in hip fracture patients
with depressive symptoms might increase susceptibility of infec-
tions in these patients, which may be a contributing factor towards
ill-health and increased risk of mortality reported in these patients.
However, the size of our study was not sufﬁcient to verify this
hypothesis even though 34.5% of the sample went onto develop
infections.
One of the possible mechanisms usually thought to mediate re-
duced neutrophil superoxide production in depressed hip fracture
patients could be altered activity of adrenal hormones, speciﬁcally
DHEAS and cortisol. Cortisol is well documented as a suppressor of
neutrophil superoxide generation (Bekesi et al., 2000; Butcher
et al., 2005) and DHEAS enhances superoxide generation in
in vitro assays (Radford et al., 2010). However our data suggest that
although altered HPA axis activity was related to depression, it did
not mediate the decrease in neutrophil function seen in depressed
patients and another mechanism is providing the link between
depression and reduced neutrophil superoxide generation. Assem-
bly and activation of the NADPH oxidase complex involving associ-
ation of cytosolic components p47phox, p67phox, and p40phox
with membrane bound gp91phox and p22phox, catalyses electron
transfer from NADPH to oxygen resulting in superoxide generation
(Babior et al., 2002). A study examining the effect of academic psy-
chological stress on neutrophil functioning reported that decreased
superoxide production was accompanied by diminished expres-
sion of subunit p47phox of NADPH complex (Ignacchiti et al.,
2011). Although not determined here, this may provide a mecha-
nism for reduced superoxide generation in the depressed hip frac-
ture patients.
Experimental and clinical evidence has suggested that depres-
sion and depressive symptoms are accompanied by elevated levels
of pro-inﬂammatory cytokines, including IL6, TNFa and IL1b (Dow-
lati et al., 2010; Leonard, 2010; Zunszain et al., 2012). In this study,
we have reported elevated levels of TNFa and IL6 in hip fracture
patients with depressive symptoms compared with patients with-
out depressive symptoms and healthy controls. This is consistent
with ﬁndings of a previous study examining cytokine levels in
hip fracture patients, according to which older hip fracture patients
with high levels of pro-inﬂammatory cytokines such as IL6 hadhigher GDS scores (Matheny et al., 2011). Epidemiological studies
have also reported an association between inﬂammatory marker
IL6 and depressive symptoms in older people (Dentino et al.,
1999; Penninx et al., 2003). Further, studies in animal models have
shown that administration of pro-inﬂammatory cytokines are
known to induce ‘sickness behaviour’ resulting in behavioural
changes including sleep disturbance, loss of appetite, memory
impairment and loss of interest in social activities that overlap
with many of the symptoms of depression in humans (Dantzer
et al., 2008; Kaster et al., 2012). A few studies conducted in older
adults have suggested that inﬂammation might play a potential
causal role in the development of depressive symptoms (Milane-
schi et al., 2009; van den Biggelaar et al., 2007), suggesting that ele-
vated levels of pro-inﬂammatory cytokines in certain hip fracture
patients might increase the risk of development of depressive
symptoms in this sub-group. As discussed previously, depression
is associated with HPA axis hyperactivity, resulting in elevated cor-
tisol levels. Interestingly, there is evidence to suggest that pro-
inﬂammatory cytokines (IL6, TNFa, IL1b) are responsible for direct
activation of the HPA axis (Dunn, 2000; Turnbull and Rivier, 1999).
Thus, inﬂammation might be a driving factor for the development
of depression. Indeed, in the present study, depressive symptoms
score was signiﬁcantly correlated with IL6 levels. However, TNFa,
and IL1b did not correlate with depressive symptoms in the pres-
ent study, nor did the hip fracture patient groups differ on these
cytokines, other than for TNFa. Further, as these pro-inﬂammatory
cytokines did not correlate with neutrophil superoxide production
among hip fracture patients, while they may have played a role in
the development of depressive symptoms, they did not mediate
the association between depressive symptoms and neutrophil
function or drive the differences in neutrophil function observed;
depression was independently associated with neutrophil super-
oxide production.
Anti-inﬂammatory cytokines, such as IL10 are responsible for
reducing production of pro-inﬂammatory cytokines and dampen-
ing immune responses (Moore et al., 2001). In this study, in addi-
tion to an elevation in levels of pro-inﬂammatory cytokines,
including IL6 and TNFa, we have also reported an elevated serum
level of anti-inﬂammatory cytokine IL10 in hip fracture patients
with depressive symptoms compared to healthy controls but not
non-depressed hip fracture patients. A similar elevation of IL10
has been previously reported in depressed individuals (Kubera
et al., 2000; Simon et al., 2008), which might be a counter regula-
tory mechanism to try to reduce inﬂammatory responses and re-
store homeostasis. However, again as IL10 was not signiﬁcantly
associated with depressive symptoms score or neutrophil function
in the present study, it is unlikely that it mediated the association
between depression and neutrophil function or drove the effects
on neutrophil function.
Hip fracture is associated with an increase in mortality that can
persist for years after the fracture. Recovery after hip fracture is a
long process and only one-third of patients have been reported
to return to their pre-fracture functional status one year after the
fracture (Magaziner et al., 2000). In an attempt to examine the long
term effect of depression on immunity we examined neutrophil
function in hip fracture patients with post-fracture depressive
symptoms at six months after surgery. We observed that a higher
cortisol:DHEAS ratio persisted at this time point but the neutrophil
superoxide generation in hip fracture patients with depression had
improved after 6 months. This further supports the proposal that
the raised cortisol:DHEAS ratio did not mediate reduced neutrophil
function in those with depressive symptoms after hip fracture.
The present study has several limitations. First, it was not pos-
sible to recruit a healthy population with depression symptoms to
compare our results with, as any individuals that we might be able
to identify from general practioner records would also be undergo-
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teria. Second, we were only able to assess cortisol and DHEAS at
one time of day. Ideally, a diurnal assessment would be undertaken
to give a more accurate fuller picture of changes in hormone secre-
tion. However, in this frail patient group, it was not practical or
ethical to increase the number of blood samples taken.
Despite reports regarding the high prevalence of depression and
depressive symptoms in hip fracture patients it still remains unde-
tected in the majority of patients and providing psychosocial care
or pharmacological treatment for depression to these patients is
rare. Recently, a nurse led intervention programme for older hip
fracture patients with depression involving regular meetings with
a psychiatric nurse and antidepressant medication proved to be a
cost-effective method for reducing depressive symptoms (Romeo
et al., 2011). Antidepressants, in addition to attenuation of depres-
sive symptoms, have also been reported to reduce neurological dis-
turbances observed in depressed patients, such as HPA axis
hyperactivity by enhancing GR-mediated negative feedback by
glucocorticoids by increasing GR expression and function. In addi-
tion to clinical interventions, proper counselling, psychological
support, broadening social involvement (Cohen et al., 1997) and
maintaining healthful practises (proper diet, exercise) may ap-
pease the deleterious effects of chronic exposure to stress and pre-
serve immune function.
In conclusion, the present study reports for the ﬁrst time that
development of depressive symptoms in older hip fracture patients
can result in suppression of neutrophil bactericidal properties,
changes in circulating levels of certain and long term altered adre-
nocortical hormone balance. These ﬁndings suggest that develop-
ment of depressive symptoms after a hip fracture in older adults
is the main driver of immune suppression, as we failed to ﬁnd an
immune decline as a result of hip fracture alone. Our ﬁndings sup-
port the need for preventing and treating depression and depres-
sive symptoms to improve outcomes in older hip fracture patients.Acknowledgments
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